Skip to content

Depression: all studies

Page 366 of 1,034: studies 3,651 to 3,660 of 10,336, newest first. Back to the depression overview

Research

Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial.

medRxiv November 2, 2024 Theresa R. Lii, Josephine R. Flohr, Robin L. Okada et al. preprint

The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant effects of ketamine versus placebo in surgical patients, some of whom were on chronic opioid therapy, revealed a substantial placebo effect. This finding provided an opportunity to test the hypothesis that opioid agonist exposure interacts with placebo...

DOI: 10.1101/2024.09.24.24314243 (opens in new tab) Full text (opens in new tab) Depression/mental health/mood disorders Opioids/painkillers/narcotics Placebo effect/placebo response Psychopharmacology/drug interactions +1

A randomized controlled clinical trial of a Wim Hof Method intervention in women with high depressive symptoms.

Comprehensive Psychoneuroendocrinology November 1, 2024 Robin Blades, Wendy Berry Mendes, Brian P Don et al.

Stress is a driver of depression, and people with depression often struggle to cope with stress and anxiety. This study directly compares the mental health effects of a Wim Hof Method intervention to an active control condition (slow breathing) in women with high stress and high depressive symptoms. We randomized 84 healthy midlife women with high stress and high depressive symptoms to either:...

Mindfulness improves psychological health and supports health behaviour cognitions: Evidence from a pragmatic RCT of a digital mindfulness-based intervention.

British Journal of Health Psychology November 1, 2024 Masha Remskar, Max J. Western, Ben Ainsworth 24 citations

Mindfulness-based interventions can improve psychological health; yet the mechanisms of change are underexplored. This pre-registered remote RCT evaluated a freely accessible digital mindfulness programme aiming to improve well-being, mental health and sleep quality. Health behaviour cognitions were explored as possible mediators. Participants from 91 countries (N = 1247, Mage = 27.03 [9.04])...

Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models.

Neuropharmacology November 1, 2024 M C Acero-Castillo, M B M Correia, F V Caixeta et al. 7 citations

Ketamine is an NMDA (N-methyl-d-aspartate) glutamate receptor antagonist, which has a myriad of dose-dependent pharmacological and behavioral effects, including anesthetic, sedative, amnestic, analgesic, and anti-inflammatory properties. Intriguingly, ketamine at subanesthetic doses displays a relevant profile both in mimicking symptoms of schizophrenia and also as the first fast-acting...

Rethinking the role of TRKB in the action of antidepressants and psychedelics.

Trends in Neurosciences November 1, 2024 Cecilia Anna Brunello, Cecilia Cannarozzo, Eero Castrén 29 citations

Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neuronal receptor tyrosine kinase 2 (NTRK2 or TRKB) is among the critical steps in this process. These mechanisms are shared by typical slow-acting antidepressants, fast-acting ketamine, and psychedelic compounds, although the cellular targets of each drug...

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action

Current Psychiatry Reports November 1, 2024 Matthew J Reid, Hannes Kettner, Tessa F. Blanken et al. 4 citations

Abstract Purpose of the study Psilocybin is a rapidly-emerging treatment for depression, yet its impact on sleep is not well understood. We sought to explore the literature on sleep and psilocybin use, and explore the topic using our own primary data. Findings Whilst clinical trials demonstrate large depressive symptom improvements, the impact of psilocybin on sleep quality or insomnia...

DOI: 10.1007/s11920-024-01539-8 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Poor sleep Depressive symptoms Adopt +6

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

European Archives of Psychiatry and Clinical Neuroscience October 28, 2024 Kaike Thiê da Costa Gonçalves, Vagner Deuel O de Tavares, Maria Luiza de Morais Barros et al. 5 citations

This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psychiatric disorders. We searched three databases and used citation tracking to include 29 studies. Predominantly, mood disorders, including bipolar disorder (BD) and major depressive disorder (MDD) (MDD + BD: + n = 25 studies), a large part of them...

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.

Current Topics in Behavioral Neurosciences October 23, 2024 Grace Viljoen, Felix Betzler 5 citations

There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Journal of Affective Disorders October 15, 2024 Angela T H Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur et al. 13 citations

Ketamine and esketamine are increasingly prescribed in the treatment of resistant mood disorders and persons at risk of suicide. Ketamine is a drug of misuse with increasing non-therapeutic use in the general population. Herein, our aim was to determine whether ketamine and/or esketamine are disproportionately associated with reports of substance and/or alcohol misuse. Replicating a similar...

Development of a mindfulness-based intervention for narcolepsy: a feasibility study.

Sleep October 11, 2024 Jennifer M Mundt, Phyllis C Zee, Matthew D Schuiling et al. 3 citations

Mindfulness-based interventions (MBI) have been shown to improve psychosocial functioning in medical populations but have not been studied in narcolepsy. This study examined the feasibility and acceptability of an MBI that was adapted for narcolepsy, including three variations in program length. Adults with narcolepsy (N = 60) were randomized to MBI groups of varying durations: brief (4 weeks),...